Convalescent plasma helps improve 76% of Covid 19 patients, finds study

HOUSTON –Convalescent plasma and hyperimmune immunoglobulin have been used successfully to treat other respiratory viruses. These treatments (given by a drip or injection) are generally well-tolerated, but unwanted effects can occur.

The country's first convalescent plasma transfusion trial results have been published and show 19 out of 25 patients improved with the treatment, and 11 were discharged from the hospital. On March 28, Houston Methodist became the first academic medical center in the nation to transfuse plasma from recovered COVID-19 patients into two critically ill patients.

With no adverse side effects caused by the plasma transfusion, the study concluded that convalescent plasma is a safe treatment option for patients with severe COVID-19 disease. To date, this is the largest cohort worldwide assessed for outcomes pertaining to convalescent plasma transfusion for COVID-19.

"While physician scientists around the world scrambled to test new drugs and treatments against the killer COVID-19 virus, convalescent serum therapy emerged as potentially one of the most promising strategies," said James M. Musser, M.D., Ph.D., chair of the Department of Pathology and Genomic Medicine at Houston Methodist. "With no proven treatments or cures for COVID-19 patients, now was the time in our history to move ahead rapidly."

Patients were first treated under emergency use guidelines (eIND) from the FDA and then received approval April 3 from the FDA to open up the trial to more patients as an investigational new drug (IND). This extraordinarily rapid approval granted by the FDA opened up access to convalescent plasma treatment for COVID-19 patients.

The century-old therapeutic approach dates back to at least as early as 1918 to fight the Spanish Flu and more recently was used with some success during the 2003 SARS pandemic, the 2009 influenza H1N1 pandemic and the 2015 Ebola outbreak in Africa. Following a study early on in the COVID-19 pandemic where a handful of critically ill patients in China showed improvement. An interdisciplinary team of Houston Methodist physician scientists and health care workers rapidly targeted the COVID-19 virus with convalescent serum therapy.

Given the urgency of finding effective treatments for COVID-19, a preliminary report that has not yet been peer-reviewed has been posted on the preprint server medRxiv. The manuscript, titled "Treatment of COVID-19 patients with convalescent plasma in Houston, Texas," has been submitted for peer-review to a prominent medical journal. This preprint is not the final version of the article. Musser is the corresponding author on the study. Eric Salazar, M.D., Ph.D., assistant professor of pathology and genomic medicine with the Houston Methodist Research Institute, is the principal investigator who led the project to treat critically ill COVID-19 patients with convalescent plasma.

Additional findings during this trial revealed patient outcomes of plasma therapy were very similar to recently published results of patients treated on a compassionate-use basis with the antiviral drug Remdesivir. The research team also concluded that any observed complications were consistent with findings reported for COVID-19 disease progression and not brought about by the plasma transfusions. The study's overall findings were consistent with several other small case studies of convalescent plasma use for severe COVID-19 that have been recently reported.

Ultimately, although the convalescent plasma therapy administered on the front lines at Houston Methodist was implemented for emergency treatment, the study's authors recognize the important need for controlled clinical trials to determine its therapeutic efficacy. A randomized controlled trial is currently being considered at Houston Methodist where they would also look more closely at variables such as timing of the transfusion after the onset of symptoms, the number and volume of transfusions adjusted for patient biometrics, antibody levels in donor plasma and numerous other parameters needed to effectively evaluate how to optimize this therapy. This would help address some questions, including whether patients would have better outcomes if plasma transfusions were administered sooner after the onset of symptoms.

Not all plasma recipients transfused so far at Houston Methodist were part of this first trial. Since late March, when the first patients were infused with convalescent plasma, Houston Methodist has treated 74 critically ill COVID-19 patients, 50 of whom have been discharged from the hospital and are recovering. More than 150 recovered COVID-19-infected people donated their plasma, many of them continuing to do so frequently.

Other collaborators on this study were Eric Salazar, Katherine K. Perez, Madiha Ashraf, Jian Chen, Brian Castillo, Paul C. Christensen, Taryn Eubank, David W. Bernard, Todd Eagar, S. Wesley Long, Sishir Subedi, Randall J. Olsen, Christopher Leveque, Mary R. Schwartz, Monisha Dey, Cheryl Chavez-East, John Rogers, Ahmed Shehabeldin, David Joseph, Guy Williams, Karen Thomas, Faisal Masud, Christina Talley, Katharine G. Dlouhy, Bevin Lopez, Curt Hampton, Jason Lavinder, Jimmy D. Gollihar, Andre C. Maranhao, Gregory C. Ippolito, Matthew Ojeda Saavedra, Concepcion C. Cantu, Prasanti Yerramilli and Layne Pruitt.

This study was supported by funding from the National Institutes of Health (grants AI146771-01 and AI139369-01), the Fondren Foundation, the National Institute of Allergy and Infectious Diseases (Contract Number 75N93019C00050), the Army Research Office (Cooperative Agreement W911NF-12-1-0390), Houston Methodist Hospital and Houston Methodist Research Institute.

For more details click on the link: doi: https://doi.org/10.1101/2020.05.08.20095471